Vera Therapeutics, Inc. (VERA) stock
VERANasdaqPharmaceutical PreparationsFiscal year ends December 31
$28.10−0.94 (-3.24%)
Close on Nov 13, 2026Market cap $2.02BP/E –Yield –
Vera Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Vera Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$426.30M. For fiscal 2025 it was -$315.01M. The highest annual figure on record is -$34.23M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$315.01M | – |
| FY2024 | Dec 31, 2024 | -$167.07M | – |
| FY2023 | Dec 31, 2023 | -$101.99M | – |
| FY2022 | Dec 31, 2022 | -$91.75M | – |
| FY2021 | Dec 31, 2021 | -$34.23M | – |
| FY2020 | Dec 31, 2020 | -$51.99M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$94.88M | – |
| Q2 FY2026 | Jun 30, 2026 | -$112.36M | – |
| Q1 FY2026 | Mar 31, 2026 | -$124.99M | – |
| Q4 FY2025 | Dec 31, 2025 | -$94.07M | – |
| Q3 FY2025 | Sep 30, 2025 | -$83.80M | – |
| Q2 FY2025 | Jun 30, 2025 | -$80.02M | – |
| Q1 FY2025 | Mar 31, 2025 | -$57.11M | – |
| Q4 FY2024 | Dec 31, 2024 | -$48.86M | – |
| Q3 FY2024 | Sep 30, 2024 | -$49.78M | – |
| Q2 FY2024 | Jun 30, 2024 | -$37.33M | – |
| Q1 FY2024 | Mar 31, 2024 | -$31.10M | – |
| Q4 FY2023 | Dec 31, 2023 | -$27.02M | – |
| Q3 FY2023 | Sep 30, 2023 | -$21.75M | – |
| Q2 FY2023 | Jun 30, 2023 | -$21.45M | – |
| Q1 FY2023 | Mar 31, 2023 | -$31.76M | – |
| Q4 FY2022 | Dec 31, 2022 | -$34.18M | – |
| Q3 FY2022 | Sep 30, 2022 | -$25.40M | – |
| Q2 FY2022 | Jun 30, 2022 | -$15.16M | – |
| Q1 FY2022 | Mar 31, 2022 | -$17.01M | – |
| Q4 FY2021 | Dec 31, 2021 | -$16.55M | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.19M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.80M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.68M | – |
| Q4 FY2020 | Dec 31, 2020 | -$43.20M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.36M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.06M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.36M | – |
See a number that looks wrong?